Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (391-400 of 525) with videos related to

Pageof 53
Sort By:
Plos Medicine|July 8, 2009
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionMarc C Levesque, M Anthony Moody, Kwan-Ki Hwang, et al.
Journal of Virology|June 5, 2015
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, et al.
Acta Neuropathologica|May 25, 2022
Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositisCorinna Preuße, Barbara Paesler, Christopher Nelke, et al.
NPJ Vaccines|April 10, 2021
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
Plos One|April 15, 2016
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesGerard Zurawski, Sandra Zurawski, Anne-Laure Flamar, et al.
JCI Insight|December 22, 2017
Computational analysis of antibody dynamics identifies recent HIV-1 infectionKelly E Seaton, Nathan A Vandergrift, Aaron W Deal, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Communications Medicine|April 24, 2025
Distinct immune responses in people living with HIV following SARS-CoV-2 recoveryDieter Mielke, Shuying Sue Li, Daniel J Schuster, et al.
Vaccines|April 23, 2025
Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV ChallengeDieter Mielke, Marina Tuyishime, Natasha S Kelkar, et al.
Pageof 53

Showing results (391-400 of 525) with videos related to

Sort By:
Pageof 53
Plos Medicine|July 8, 2009
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionMarc C Levesque, M Anthony Moody, Kwan-Ki Hwang, et al.
Journal of Virology|June 5, 2015
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, et al.
Acta Neuropathologica|May 25, 2022
Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositisCorinna Preuße, Barbara Paesler, Christopher Nelke, et al.
NPJ Vaccines|April 10, 2021
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
Plos One|April 15, 2016
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus MacaquesGerard Zurawski, Sandra Zurawski, Anne-Laure Flamar, et al.
JCI Insight|December 22, 2017
Computational analysis of antibody dynamics identifies recent HIV-1 infectionKelly E Seaton, Nathan A Vandergrift, Aaron W Deal, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Communications Medicine|April 24, 2025
Distinct immune responses in people living with HIV following SARS-CoV-2 recoveryDieter Mielke, Shuying Sue Li, Daniel J Schuster, et al.
Vaccines|April 23, 2025
Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV ChallengeDieter Mielke, Marina Tuyishime, Natasha S Kelkar, et al.
Pageof 53